Dermatology Times has published the second installment in its case-based series on hidradenitis suppurativa (HS), addressing a clinical scenario that guidelines answer only partially: what to do when a biologic agent fails to control disease. The piece, titled "Case 2: Escalating Therapy After Biologic Failure in HS," examines escalation strategy in a condition where approved options remain scarce.

The framing matters. HS, a chronic inflammatory follicular disorder producing painful nodules, abscesses and sinus tracts — predominantly in axillary, inguinal and inframammary skin — has long outgrown its mislabel as a hygiene or infection problem. Yet the therapeutic arsenal has not kept pace with that recognition.

Why does biologic failure dominate the HS conversation?

Only a limited set of biologic agents carries regulatory approval for HS, and real-world cohorts routinely include patients who lose response or never achieve adequate control on those agents. Primary non-response and secondary loss of efficacy, phenomena familiar from psoriasis practice, force clinicians into territory where trial evidence thins out quickly.

That is precisely the gap the Dermatology Times case series targets. By structuring the discussion around a single patient trajectory rather than a trial population, the format exposes the reasoning clinicians actually apply: when to classify a regimen as failed, what to switch to, and how to weigh combination approaches against sequential monotherapy.

What does "escalation" actually mean here?

The case format invites a distinction the source title implies but does not spell out. Escalation can mean switching within the approved biologic class, moving to an off-label systemic agent, or layering medical therapy onto surgical intervention for fixed sinus tracts. Each path carries a different evidence class, and the case-based literature in HS has historically been better at describing the options than comparing them.

A caveat belongs here, as it does with every case report: a single-patient narrative, however instructive, cannot establish comparative effectiveness. What works in one Hurley-stage presentation — Hurley staging being the three-tier severity scale used in HS — may not transfer to another. Readers should treat the case as decision-support scaffolding, not as a protocol.

What the source does not say

The Dermatology Times piece, as presented, offers a title and a clinical premise; it does not, in the material available, name the specific agent that failed, the escalation chosen, or the outcome achieved. That absence is itself telling. Biologic failure in HS is discussed frequently at congresses and in review articles, yet published case detail — dosing, timing, response duration — remains uneven.

For a clinician audience, the practical question is not whether escalation is sometimes necessary. It clearly is. The question is whether the field will generate the comparative data — ideally randomized switch trials rather than accumulated anecdotes — that turn escalation from judgment call into algorithm. Until then, series like this one fill an educational gap, with all the limitations that implies.

How dermatology journals and societies formalize post-biologic pathways in HS will determine whether the next iteration of these cases cites evidence or, once again, experience.